Information Provided By: 
Fly News Breaks for July 10, 2019
AERI
Jul 10, 2019 | 09:05 EDT
Needham analyst Serge Belanger lowered his price target on Aerie Pharmaceuticals to $74 to reflect the slower than expected sales ramp of Rhopressa based on the IQVIA bottle count data as well as the worse than expected launch of Rocklatan. The analyst maintains his Buy rating on Aerie Pharmaceuticals however despite the stock price falling toward its 52-week lows with a positive long-term thesis on the potential of its glaucoma franchise.
News For AERI From the Last 2 Days
There are no results for your query AERI
